Dr. Lal Path Labs Ltd. (LALPATHLAB) fundamentals
Dr. Lal Path Labs Ltd. is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as LALPATHLAB (ISIN INE600L01024). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Dr. Lal Path Labs Ltd. does
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
Valuation and market data
| Last close | ₹1909.00 |
|---|---|
| Market capitalisation | ₹32,180 crore |
| Enterprise value | ₹32,091 crore |
| P/E (TTM) | 63.13 |
| Price to book | 12.66 |
| Price to sales (TTM) | 6.39 |
| Book value per share | ₹150.76 |
| Dividend yield | 102.15% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Wed Dec 23 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,864 crore | ₹669 crore | ₹510 crore | 30.24 |
| Mar 2025 | ₹2,555 crore | ₹625 crore | ₹492 crore | 58.48 |
| Mar 2024 | ₹2,296 crore | ₹505 crore | ₹362 crore | 43.05 |
| Mar 2023 | ₹2,059 crore | ₹344 crore | ₹241 crore | 28.82 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 53.2% |
|---|---|
| Foreign institutions (FII) | 17.4% |
| Mutual funds | 18.8% |
| Other domestic institutions | 2.8% |
| Retail and others | 7.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.